ダウンロード数: 243
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
38_1293.pdf | 350.21 kB | Adobe PDF | 見る/開く |
タイトル: | 進行性腎細胞癌に対するインターフェロン療法の現況と展望 |
その他のタイトル: | Interferon therapy for advanced renal cell carcinoma |
著者: | 藤田, 民夫 福島, 雅典 |
著者名の別形: | Fujita, Tamio Fukushima, Masanori |
キーワード: | Renal cell carcinoma Interferon-alpha |
発行日: | Nov-1992 |
出版者: | 泌尿器科紀要刊行会 |
誌名: | 泌尿器科紀要 |
巻: | 38 |
号: | 11 |
開始ページ: | 1293 |
終了ページ: | 1298 |
抄録: | 1)連日筋注で300万単位のHLBIを投与した25例の第二相試験で, CR 3例, PR 3例であった。奏効症例は全例前治療に腎摘を受けており, PSも非奏効症例に比べ良好であった。2)無作為比較試験で16例に300万単位を投与し, 15例に100万単位を投与した。300万単位群の奏効率は33.1%, 100万単位群の奏効率は20.0%と有意差を認めなかった。抗腫瘍効果が見られた転移部位は全例肺であった。副作用としての血液毒性の頻度は300万単位群43.8%, 100万単位群13.3% To determine the effect of human lymphoblastoid interferon (HLBI) on metastatic renal cell carcinoma (MRCC), we performed two clinical trials. First, between 1982 and 1984, we performed a phase II study using 3 mega-units (MU) of HLBI daily in 25 eligible patients with MRCC. Six patients (24.0%) showed objective responses, including 2 with complete response (CR) and 4 with partial response (PR). Patients with a prior nephrectomy or with a good performance status were likely to respond to the therapy. Based on the above observation, we performed a prospective randomized trial to compare 2 different doses of HLBI following nephrectomy. Treatment consisted of HLBI, 3 MU intramuscularly 6 days a week in arm A and 1 MU intramuscularly 6 days a week in arm B. Treatments were started within 4 weeks after the nephrectomy and patients were evaluated every week for 1 month, and every month thereafter. Between 1985 and 1991, 16 patients were enrolled in arm A and 15 patients in arm B. Responses were seen in 5 (31.3%) of the 16 arm A patients (4 CRs and 1 PR) and 3 (20.0%) of the 15 arm B patients (1 CR and 2 PRs). Most responses occurred in patients with lung metastasis and favorable PS. There was no statistical difference in efficacy between the two arms. Hematologic toxicity was more frequent in arm A (43.8%) than arm B (13.3%). We conclude that further studies are needed to secure the clinical efficacy of HLBI for MRCC. |
URI: | http://hdl.handle.net/2433/117695 |
PubMed ID: | 1485584 |
出現コレクション: | Vol.38 No.11 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。